Squarepoint
ANIP icon

Squarepoint’s ANI Pharmaceuticals ANIP Stock Holding History

Squarepoint’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.89M Buy
63,538
+14,070
+28% +$1.1M 0.01% 1521
2025
Q4 		$3.91M Sell
49,468
-24,175
-33% -$2.09M ﹤0.01% 1609
2025
Q3 		$6.75M Buy
73,643
+40,899
+125% +$3.33M 0.01% 1290
2025
Q2 		$2.14M Buy
+32,744
New +$2.13M ﹤0.01% 2053
2021
Q4 		– Sell
-14,882
Closed -$488K – 3140
2021
Q3 		$488K Sell
14,882
-5,850
-28% -$182K ﹤0.01% 1978
2021
Q2 		$727K Buy
20,732
+7,580
+58% +$258K ﹤0.01% 1857
2021
Q1 		$475K Buy
+13,152
New +$412K ﹤0.01% 2064
2020
Q3 		– Sell
-6,842
Closed -$221K – 2469
2020
Q2 		$221K Buy
+6,842
New +$245K ﹤0.01% 1777
2020
Q1 		– Sell
-15,810
Closed -$975K – 1837
2019
Q4 		$975K Buy
+15,810
New +$1.05M 0.01% 1345
2019
Q3 		– Sell
-17,372
Closed -$1.43M – 2319
2019
Q2 		$1.43M Buy
17,372
+8,830
+103% +$628K 0.01% 1039
2019
Q1 		$603K Sell
8,542
-6,030
-41% -$355K 0.01% 1385
2018
Q4 		$656K Buy
+14,572
New +$764K 0.01% 1106
2018
Q2 		– Sell
-3,796
Closed -$221K – 1731
2018
Q1 		$221K Sell
3,796
-16,954
-82% -$1.08M ﹤0.01% 1453
2017
Q4 		$1.34M Buy
+20,750
New +$1.29M 0.02% 702
2017
Q3 		– Sell
-6,097
Closed -$285K – 1599
2017
Q2 		$285K Buy
+6,097
New +$294K 0.01% 1152
2017
Q1 		– Sell
-4,088
Closed -$248K – 1508
2016
Q4 		$248K Buy
4,088
+184
+5% +$11.3K 0.01% 1271
2016
Q3 		$259K Buy
+3,904
New +$244K 0.02% 791
2016
Q2 		– Sell
-18,645
Closed -$628K – 1087
2016
Q1 		$628K Buy
18,645
+7,700
+70% +$261K 0.05% 532
2015
Q4 		$494K Buy
+10,945
New +$471K 0.05% 541

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint's ANIP Position: Q1 2026 in Review

Squarepoint increased its ANI Pharmaceuticals (ANIP) stake by 28% in Q1 2026, buying an estimated $1.1M and bringing the position to 63,538 shares worth $4.89M. The position accounts for 0.01% of the portfolio, ranked #1521.

Squarepoint first reported a position in ANIP in Q4 2015 and has held it in 19 quarters since. The position peaked at $6.75M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Squarepoint held 63,538 shares of ANI Pharmaceuticals worth $4.89M as of Q1 2026.
  • Squarepoint bought 14,070 ANI Pharmaceuticals shares in Q1 2026, an estimated $1.1M.
  • ANI Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1521 holding.
  • Squarepoint first reported a position in ANI Pharmaceuticals in Q4 2015 and has held it in 19 quarters since.
  • Squarepoint's ANI Pharmaceuticals position peaked at $6.75M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.